For the Inventor, By the Inventor

Enter assignee name

Philadelphia, PA, United States of America

Thomas Jefferson University

USPTO Granted Patents = 539

% Expired Patents = 10.9

CIPO Patents = 8

EPO Patents = 31

Trademarks = 24

Forward Citations = 13,020

Loading Chart...

Loading Chart...

547 inventors (with patents filed for the assignee):

Scott A Waldman (43 out of 43 patents)

Carlo M Croce (28 out of 110 patents)

Emad S Alnemri (27 out of 34 patents)

4. Jeffrey I Joseph (26 out of 29 patents)

5. Jewell L Osterholm (22 out of 22 patents)

6. Douglas Craig Hooper (19 out of 19 patents)

7. Stephanie Schulz (15 out of 15 patents)

8. Darwin J Prockop (14 out of 42 patents)

9. Renato L Baserga (14 out of 15 patents)

10. David W Andrews (13 out of 13 patents)

11. Gerald Litwack (13 out of 21 patents)

12. Nance K Dicciani (13 out of 15 patents)

13. Denise L Devine (13 out of 15 patents)

14. Eric B Kmiec (12 out of 25 patents)

15. Matthias Johannes Schnell (12 out of 13 patents)

Core Competencies:

Cancer Treatment

Antiviral Agents

Fusion Proteins

Vaccine Development

Extracellular Vesicles

RNA Inhibitors

Microbubbles

Immunotherapy

Therapeutic Antibodies

Biomaterials

Neurodegenerative Diseases

Pathogen-Specific T Cells

539 patents: Sort by Forward Citations

1. 12766221 - Injectable, cross-linkable and subcellular size microfibers for soft tissue repair (2026-10-20),

2. 12758632 - Desmoglein 2-directed chimeric antigen receptor (CAR) constructs and methods of use (2026-10-13),

3. 12758623 - ANTI-GUCY2C VACCINE COMPOSITIONS AND METHODS OF USING THEM (2026-10-13),

4. 12741088 - Continuous subcutaneous insulin infusion catheter (2026-09-22),

5. 12700097 - Quantitative framework for the diagnostic, prognostic, and therapeutic evaluation of spinal cord diseases (2026-08-04),

6. 12582619 - Compounds, compositions, and methods for treating or ameliorating, or preventing viral infections (2026-03-24),

7. D1107915 - Biodiffusion chamber (2025-12-30),

8. 12508285 - Oligodendrocyte-derived Extracellular Vesicles for Therapy of Multiple Sclerosis (2025-12-30),

9. 12497439 - MULTI-FUNCTIONAL FUSION PROTEINS AND USES THEREOF (2025-12-16),

10. 12472199 - P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION (2025-11-18),

11. 12472151 - DELIVERY COMPOSITIONS, AND METHODS OF MAKING AND USING SAME (2025-11-18),

12. 12453539 - Midstream urine collection (2025-10-28),

13. 12447147 - Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions (2025-10-21),

14. 12390143 - Signal processing method for distinguishing and characterizing high-frequency oscillations (2025-08-19),

15. 12378322 - Fusion proteins that facilitate cancer cell destruction (2025-08-05),

Company Overview

Thomas Jefferson University, located in Philadelphia, PA, is a prominent institution specializing in cancer therapy and related biomedical research. The university focuses on innovative approaches in cancer treatment, including the development of antiviral agents, fusion proteins, and vaccines. Its research extends to cutting-edge technologies such as extracellular vesicles, RNA inhibitors, microbubbles, and immunotherapy, positioning it as a leader in advancing therapeutic solutions for cancer and other diseases.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

539 Patents

#7 in Philadelphia, PA

#38 in Pennsylvania

#912 in US

#1,811 in the World

Philadelphia, PA, United States of America

Thomas Jefferson University

Forward Citations = 13,020

547 inventors:

Scott A Waldman (43 out of 43 patents)

Carlo M Croce (28 out of 110 patents)

Emad S Alnemri (27 out of 34 patents)

4. Jeffrey I Joseph (26 out of 29 patents)

5. Jewell L Osterholm (22 out of 22 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Thomas Jefferson University. Retrieved from https://idiyas.com/company/thomas-jefferson-university

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…